Filter Results
:
(928)
Show Results For
-
All HBS Web
(928)
- People (2)
- News (64)
- Research (756)
- Events (1)
- Multimedia (2)
- Faculty Publications (649)
Show Results For
-
All HBS Web
(928)
- People (2)
- News (64)
- Research (756)
- Events (1)
- Multimedia (2)
- Faculty Publications (649)
- Web
Winners & Runners-up - New Venture Competition
magazine and store to purchase full-size products. Palliative Care of America David Matly, Michael Matly Business Track Runner-Up Palliative Care of America provides the best quality of life for seriously and terminally ill patients by providing View Details
- 01 Jun 2024
- News
Quantum Leap
pharmaceutical and chemical industries have taken note: The venture capital arm of the pharma giant Merck, for instance, invested $5 million in SEEQC’s Series A round, where it was joined by the South Korean...
View Details
- Web
For Recruiters - Health Care
systems, e-health firms, pharmaceutical companies, medical device manufacturers, and biotechnology companies. Hire a Summer Intern Summer internships are valuable for both employers and students as a “test run.” Employers benefit most...
View Details
- 28 Apr 2009
- First Look
First Look: April 28, 2009
tilted towards old age than annuities. Several advantages of this are discussed, including some that may explain why tontines have proven popular with consumers in the past. Download the paper: http://www.hbs.edu/research/pdf/09-121.pdf PublicationsWhere Is the...
View Details
Keywords:
Martha Lagace
- October 2004 (Revised July 2010)
- Case
Product Team Cialis: Getting Ready to Market
By: Elie Ofek
Lilly and ICOS are preparing for the launch of a new drug, Cialis, to compete against Viagra. To position against the incumbent firm Pfizer, which developed and markets Viagra, and other newcomers into the erectile dysfunction market, they must determine how best to...
View Details
Keywords:
Communication Strategy;
Marketing Strategy;
Product Launch;
Product Positioning;
Competition;
Competitive Advantage;
Segmentation;
Pharmaceutical Industry
Ofek, Elie. "Product Team Cialis: Getting Ready to Market." Harvard Business School Case 505-038, October 2004. (Revised July 2010.)
- July 2009 (Revised May 2010)
- Case
Pfizer: Letter from the Chairman (A)
By: Robert L. Simons and Natalie Kindred
This case explores maximizing shareholder value as a goal in executive decision making. Over a period of nine years, three different Pfizer CEOs make critical decisions intended to increase shareholder value. But the results are disappointing. To allow students to...
View Details
Keywords:
Decision Choices and Conditions;
Corporate Accountability;
Corporate Governance;
Annual Reports;
Business and Shareholder Relations;
Value Creation;
Pharmaceutical Industry;
United States
Simons, Robert L., and Natalie Kindred. "Pfizer: Letter from the Chairman (A)." Harvard Business School Case 110-003, July 2009. (Revised May 2010.)
- Web
Vault | Baker Library | Bloomberg Center | Harvard Business School
Hotels Investment Banking Pharmaceuticals Retail & Luxury Goods Sustainability Technology Database AttributesCategories Career Guides Career Resources General Industry Information Keywords View Details
John A. Deighton
John Deighton is The Harold M. Brierley Professor of Business Administration Emeritus at Harvard Business School. He is an authority on consumer behavior and marketing, with a focus on digital and direct marketing. He teaches in the area of Big Data in Marketing,... View Details
Keywords:
e-commerce industry;
e-commerce industry;
e-commerce industry;
e-commerce industry;
e-commerce industry;
e-commerce industry;
e-commerce industry;
e-commerce industry;
e-commerce industry;
e-commerce industry;
e-commerce industry;
e-commerce industry;
e-commerce industry;
e-commerce industry;
e-commerce industry;
e-commerce industry
- 01 Dec 2019
- News
Remix
community after their respective accusations against Clarence Thomas and Mike Tyson. It’s one of the factors that helps explain why women of color report sexual assault at rates far below that of white women and a major force behind Dixon’s decision to leave the View Details
- Web
Globalization - Faculty & Research
Dilemmas: Novo Nordisk’s Weight Loss DrugsBy: Joseph L. Badaracco, Tom Quinn and John Schultz April 2024 (Revised April 2024) | Case | Faculty Research Danish pharmaceutical company Novo Nordisk was owned by a charitable foundation, and...
View Details
- Web
Recruiting Partners - Health Care
Kearney, Inc. Abbott ABILITY Network, Inc. Abpro Accolade Adimab, Inc. Advance Technological Radiology PA Advantage Healthcare Inc. Advocates Aetna Agilent Technologies AGION Technologies Aledade Alkermes Allen Institute for Brain Science Allergan Almata Health Alnylam...
View Details
- Web
Stat Plus | Baker Library | Bloomberg Center | Harvard Business School
Pharmaceuticals Database AttributesCategories Industry Specific Databases Industry Specific News Keywords health tech industry overview medical...
View Details
- December 2017 (Revised January 2018)
- Case
Alltech
By: David E. Bell and Natalie Kindred
Alltech was a Lexington, Kentucky–based producer of supplements for animal feed, with revenues of over $2 billion (projected to reach $3 billion in 2018), sales in 120 countries, 5,000 employees, and 100 manufacturing plants worldwide. For nearly four decades, Alltech...
View Details
Keywords:
Alltech;
United States;
Agribusiness;
Agriculture;
Animal;
Animal Agriculture;
Animal Feed;
Livestock;
Family Business;
Vertical Integration;
Strategy;
Growth;
Feed Additives;
Feed Supplements;
Kentucky;
Growth Strategy;
Family Businesses;
Animal-Based Agribusiness;
Acquisition;
Business Growth and Maturation;
Business Model;
Change Management;
Trends;
Governance;
Entrepreneurship;
Growth and Development;
Intellectual Property;
Leadership;
Management;
Markets;
Organizational Culture;
Private Ownership;
Science;
Quality;
Risk and Uncertainty;
Research;
Sales;
Agriculture and Agribusiness Industry;
Agriculture and Agribusiness Industry;
United States;
Kentucky;
Brazil;
China
Bell, David E., and Natalie Kindred. "Alltech." Harvard Business School Case 518-001, December 2017. (Revised January 2018.)
- 30 Oct 2007
- First Look
First Look: October 30, 2007
Changing Context of Pharmaceutical Risk Mitigation Author:Arthur A. Daemmrich Periodical:Pharmacy in History 49, no. 2 (2007): 61-75 Abstract In the wake of Vioxx, Avandia, and other recent prominent cases of drugs found to cause side...
View Details
Keywords:
Sean Silverthorne
- Web
Informa (In Vivo, MedTech Insight, Scrip) | Baker Library | Bloomberg Center | Harvard Business School
platform. Related Resources Medical Devices Pharmaceuticals Database AttributesCoverageIn Vivo - latest 3 months; MedTech - Most recent 1 year(s) 6 month(s) available; Start-up?Categories Industry Specific...
View Details
- 17 Jan 2008
- Working Paper Summaries
Competition in Modular Clusters
Joey Ryu
Joey (Won Jung) Ryu is a doctoral student in the Strategy unit at Harvard Business School. Her primary interests are strategic management, economics of innovation and entrepreneurship. Prior to joining HBS, Joey recieved her master's degree from Cornell University...
View Details
- October 2022
- Case
Cost Plus Drugs
By: Alexander MacKay and James Barnett
In September 2022, Mark Cuban Cost Plus Drugs Company CEO Alex Oshmyansky considered the future of the company. Cost Plus Drugs was a retailer for more than 340 generic oral medications, selling their drugs at significantly lower prices than typical pharmacies....
View Details
Keywords:
Business Ventures;
Decision Making;
Entrepreneurship;
Ethics;
Health;
Markets;
Social Enterprise;
Society;
Strategy;
Health Care and Treatment;
Business Divisions;
Factories, Labs, and Plants;
Health Industry;
Health Industry;
United States;
Texas
MacKay, Alexander, and James Barnett. "Cost Plus Drugs." Harvard Business School Case 723-362, October 2022.
- December 2019
- Case
The Business of Pain: Johnson & Johnson and the Promise of Opioids
By: Erik Snowberg, Trevor Fetter and Amy W. Schulman
This case is designed to provide an engrossing overview of stakeholder capitalism through a vigorous discussion of the conflicts that can arise when trying to serve multiple stakeholders.
In 2007, Johnson & Johnson’s (J&J) subsidiary Janssen has to decide whether or...
View Details
Keywords:
Opioids;
Addiction;
Stakeholder Capitalism;
Business and Stakeholder Relations;
Product Launch;
Decision Making;
Ethics;
Social Issues;
Pharmaceutical Industry
Snowberg, Erik, Trevor Fetter, and Amy W. Schulman. "The Business of Pain: Johnson & Johnson and the Promise of Opioids." Harvard Business School Case 720-420, December 2019.
- 01 Sep 2007
- News
Alfred D. Chandler Jr. Remembered
Matsushita. That volume was followed in 2005 by Shaping the Industrial Century: The Remarkable Story of the Evolution of the Modern Chemical and Pharmaceutical Industries. “Such science-based View Details